Such hypothesis is supported by the observations that high tumor density of CD8 T cells [6,7], high Interferon-γ (IFNγ)-related gene expression signature within the tumor [8], and high tumor mutational burden [9,10,11] all are associated with response to checkpoint inhibitors in melanoma patients. Here, CD8A is linked to neoplasm.